Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Cantor Fitzgerald reiterated their overweight rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research report ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Fintel reports that on November 26, 2024, Morgan Stanley downgraded their outlook for Alector (NasdaqGS:ALEC) from ...

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...